Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data ; volume:41 ; number:12 ; day:28 ; month:10 ; year:2024 ; pages:4581-4590 ; date:12.2024
Advances in therapy ; 41, Heft 12 (28.10.2024), 4581-4590, 12.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-03023-4
- URN
-
urn:nbn:de:101:1-2501272121345.727301766811
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chaudhuri, Nazia
- Azuma, Arata
- Sroka-Saidi, Kamila
- Erhardt, Elvira
- Ritter, Ivana
- Harari, Sergio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Interstitial lung diseases in children
Interstitial Fluid Behavior and Diseases
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Interstitial lung diseases in children
Interstitial Fluid Behavior and Diseases
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Interstitial lung diseases in children